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Abstract
Background: Recently it has been shown that radiation induces migration of glioma cells and facilitates a further
spread of tumor cells locally and systemically. The aim of this study was to evaluate whether radiotherapy induces
migration in head and neck squamous cell carcinoma (HNSCC). A further aim was to investigate the effects of
blocking the epidermal growth factor receptor (EGFR) and its downstream pathways (Raf/MEK/ERK, PI3K/Akt) on
tumor cell migration in vitro.
Methods: Migration of tumor cells was assessed via a wound healing assay and proliferation by a MTT
colorimeritric assay using 3 HNSCC cell lines (BHY, CAL-27, HN). The cells were treated with increasing doses of
irradiation (2 Gy, 5 Gy, 8 Gy) in the presence or absence of EGF, EGFR-antagonist (AG1478) or inhibitors of the
downstream pathways PI3K (LY294002), mTOR (rapamycin) and MEK1 (PD98059). Biochemical activation of EGFR
and the downstream markers Akt and ERK were examined by Western blot analysis.
Results: In absence of stimulation or inhibition, increasing doses of irradiation induced a dose-dependent
enhancement of migrating cells (p < 0.05 for the 3 HNSCC cell lines) and a decrease of cell proliferation (p < 0.05
for the 3 HNSCC cell lines). The inhibition of EGFR or the downstream pathways reduced cell migration
significantly (almost all p < 0.05 for the 3 HNSCC cell lines). Stimulation of HNSCC cells with EGF caused a
significant increase in migration (p < 0.05 for the 3 HNSCC cell lines). After irradiation alone a pronounced
activation of EGFR was observed by Western blot analysis.
Conclusion: Our results demonstrate that the EGFR is involved in radiation induced migration of HNSCC cells.
Therefore EGFR or the downstream pathways might be a target for the treatment of HNSCC to improve the
efficacy of radiotherapy.
Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer worldwide [1]. In case of
a primary radiotherapy patients get no surgery. There-
fore radiation doses need to be higher than in those
cases where the patient gets surgery and a postoperative
adjuvant radiotherapy.
Anti-neoplastic properties of ionizing radiation are
primarily related to DNA damage. This treatment is an
established measure for HNSCC therapy [2,3]. Despite
technological advances and increased radiation intensity
only approximately half of the patients get cured [4].
The outcome of patients presenting more advanced
stages is even poorer, with 5-year actuarial survival rates
of about 30% [5]. These findings underscore the need to
develop novel strategies in the management of patient
with advanced HNSCC.
In the last decade significant progress has been made
in the understanding of the molecular mechanisms that
are responsible for human cancer development and pro-
gression. The epidermal growth factor receptor (EGFR),
a member of the structurally related erbB family of
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development and progression in a large number of
tumors including HNSCC [6]. EGFR over-expression
occurs early in the pathogenesis of HNSCC [7] and is
associated with reduced relapse-free survival or poor
overall survival time [8]. Also a new study shows, that
EGFR protein levels strongly predict for patient outcome
in HNSCC [9]. At a clinical level, inhibition of EGFR
with monoclonal antibody showed therapeutic effects
with better survival of patients when added to standard
radiotherapy [10]. In advanced or metastatic tumors
cetuximab plus chemotherapy had significant effects
compared with chemotherapy alone on outcome of
overall survival and progression-free survival [11].
Interestingly, in a glioma cell model it has been shown
that sublethal irradiation promotes migration and inva-
sion of tumor cells [12].
It has been shown on a molecular level that radiation
induces an overexpression of EGFRs in many HNSCC
[7,13,14]. Cassell et al. mentioned that inhibition of
EGFR with a monoclonal antibody (cetuximab, Erbi-
tux™), enhanced the development of more effective
HNSCC treatments. But there is a need of a prospective
identification of patients who would benefit from such a
therapy [15]. Besides, a phase III randomised trial has
shown that the combination of radiotherapy with the
EGFR antibody cetuximab significantly improves overall
survival at 5 years [16].
Molecular research has identified a host of new biolo-
gical parameters with potential predictive utility. Onco-
genes, tumor suppressor genes, cell-cycle control genes,
apoptosis genes and angiogenesis genes have been
extensively studied and correlated with radiation
response [17,18].
Akt (protein kinase b) as a possible response modula-
tor has recently fostered molecular strategies which
employ blockade of the receptor to down-regulate
tumor growth [19]. Besides, inhibition of Rhokinase or
PI3 kinase decreases tumor growth and cisplatin resis-
tance in HNSCC [20]. Also, expression levels of phos-
phorylated Akt and mTOR are higher in HNSCC than
in non-cancer patients [21].
The PI3K dependent pathway and the ERK pathway
are important pathways for tumor biology [22]. Raf/
MEK/ERK connect mitogen signals [23], whereas the
PI3K dependent activation of the Akt seems to be
important for anti-apoptosis and migration [24,25] (Fig-
ure 1).
The purpose of our study was twofold: (1) to investi-
gate radiation induced migration of the well established
HNSSC cell lines (BHY, CAL-27 and HN) and (2) to
investigate the possibility of inhibiting migration by
blocking the EGF receptor pathways.
Methods
Cell culture and irradiation
The cell lines HN, BHY [26] and CAL-27 [27] were
used (DSMZ, Braunschweig, Germany). Cells were
grown in Dulbecco’s modified Eagle medium (DMEM)
or Roswell park memorial institute medium (RPMI
1640) (Invitrogen, Karlsruhe, Germany) containing 10%
fetal calf serum, 2 mM glutamine, and 100 μg/ml peni-
cillin/streptomycin and maintained at 37°C in an atmo-
sphere of 5% CO2 grown to a 70-90% confluence.
Irradiation was performed at the Department of
Radiotherapy (Technical University of Munich). Cells
were X-irradiated with single doses of 2, 5 or 8 Gy with
a Philips RT 100 (Philips, Amsterdam) operated at 300
kV with 1.4 mm copper half-value layer at a dose rate
of approximately 1 Gy/min. The dose inhomogeneity
was ± 2%. The sham-treated group (0 Gy, control) was
subjected to the same protocol as exposed cells.
Wound healing assay
Investigation of cell migration capability after irradiation
treatment was performed by a modified wound healing
assay, as described before [28]: Briefly, treated and
untreated cells were grown to confluent monolayers.
Immediately before irradiation the inhibitors rapamycin
(100 nM) (Biomol, Hamburg, Germany), LY294002 (50
μM) (Calbiochem, Darmstadt, Germany), PD98059 (50
μM) (Biomol, Hamburg, Germany), tyrphostin AG1478
(10 μM) (Merck, Darmstadt, Germany) or the epidermal
growth factor (EGF) (10 ng/ml) (Upstate, Billerica, USA)
were separately added to the medium. After that, the
monolayers were wounded by scratching the surface as
uniformly as possible with a 200 μl pipette tip (Sarstedt
AG & Co., Nümbrecht, Germany). After irradiation cells
were cultivated for another 12 hrs. This initial wounding
(0 hr) and the movement of the cells in the scratched
area were photographically monitored under an inverted
light microscope (field of view by a 40 fold magnifica-
tion - Axiovert 25, Carl Zeiss AG, Göttingen, Germany,
equipped with an Olympus SC 35 Camera, Volketswil,
Switzerland). Migrating cells were counted 12 hours
after irradiation (Figure 2). These time points were cho-
sen because in former experiments all cells were grown
to confluence after 36 hours (data not shown).
Modified Boyden chamber
To confirm the results of the scratch test we analyzed
the migration by a modified Boyden chamber. Cells
were given to a transwell permeable polycarbonate
membrane with a pore size of 0.8 μm (Corning Incorpo-
rated, New York, USA). Inhibitors were added in the
medium above and under the membrane then irradia-
tion were done. 12 hrs later cells above the membrane
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Thereafter cells were counted under a microscope.
These experiments were performed to show consistent
and comparable results of radiation induced migration.
Proliferation assessment
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide] assay (Roche Diagnostics, Penzberg,
Germany) was used to assess cell proliferation, as pre-
viously described [29]. Briefly, cells were plated on 96-
well plates at a concentration of 1000 cells/well. The
above-mentioned inhibitors were added 12 hours prior
to irradiation. After incubation, and 12, 24 and 72 hours
after irradiation, 10 μl of MTT solution was added to
each well for four hours (37°C). Subsequently, 100 μlo f
dimethylsulfoxide was added to each well, yielding
purple solution. The optical density was measured at
590 nm using an ELISA reader (ASYS Hitech, Eugen-
dorf, Germany) and ratios in relation to controls were
made. All experiments were performed eight times (n =
8).
Immunoblot analysis
Immunoblot analysis was performed to determine EGFR
expression including its downstream proteins ERK and
Akt. 12 hours after irradiation, cells were harvested in
lysis buffer (Cell Lysis Buffer, New England Biolabs, Ips-
wich, USA) at 4°C. Lysates were centrifuged (10000
rpm) for 15 minutes at 4°C to remove insoluble compo-
nents. Protein content was quantified by the Bio-Rad Dc
protein assay (Bio Rad, Hercules, USA). Equal amounts
of protein were separated on SDS-PAGE 10% or 12.5%
 
Figure 1 Components of the EGFR pathways and their specific inhibitors. EGFR (Epidermal growth factor receptor), PIP2, PIP3
(Phosphatidylinositol-4,5-bisphosphate (PIP2), Phosphatidylinositol 3,4,5-trisphosphate (PIP3), MAPK/ERK (mitogen activited proteinkinase), mTOR/
FRAP (Mammalian target of rapamycin), PI3K (Phosphatidylinositol-3’-Kinase), PKB/Akt (Proteinkinase B), PTEN (Phosphatase and tensin homologue
deleted on chromosome ten).
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membrane (Millipore, Billerica, USA). The membranes
were blocked with 5% nonfat dry milk in Tris-buffered
saline containing 0,1% Tween 20 (TBST) and afterwards
incubated with primary antibody in 5% nonfat dry milk
in TBST, followed by secondary antibody linked to rab-
bitradish peroxidase diluted in 5% nonfat dry milk in
TBST. ECL Detection System for Western blot Analysis
(Amersham, Freiburg, Germany) was used according to
the manufacturer’s instructions. The Imager SRX-101°
(Konica Minolta, Langenhagen, Germany) was used to
detect bands of appropriate sizes. The following antibo-
dies were used: phospho-EGFR (Tyr1068), phospho-Akt
(Ser473), PKB/Akt, phospho-p44/42 ERK (Thr202/
Tyr204), p44/42 ERK, phospho-Raf (Ser259), phospho-
MEK1/2, and MEK1/2. All antibodies were obtained
from Cell Signaling Technology, (Boston, USA) and
used at a dilution of 1:1000.
Data and statistical analysis
For the investigation of cell migration, a two-factorial
design was considered with the factors “treatment” (con-
trol, EGF, LY294002, PD98059, rapamycin, AG1478)
and radiation dose (ranging from 0 Gy to 8 Gy). The
whole analysis was repeated n = 9 times. Cell prolifera-
tion was investigated for all six treatments, for doses 0
Gy and 8 Gy only. For each dose and each group, the
sample size was n = 8. In the whole study, the cells
were randomly assigned to the treatment groups and
radiation doses.
Radiation induced migration was assessed in a linear
regression model were migration was set as dependent
variable and the radiation dose as the metric predictor.
The potential dose dependent inhibition or enhance-
ment of migration through stimulation was investigated
based on a generalized least squares model fitted with
the R function ‘gls’ with the migration as dependent
variable. The predictors were: the radiation dose (metric
predictor, coefficient brad), the treatment (categorical
predictor with coefficients bEGF, bAG, etc and controls as
reference category), and their interactions (coefficients
brad.EGF, brad.AG, etc). A uniform correlation structure
was assumed within each of the n = 9 experiments, cor-
responding to a linear mixed model with a random for-
est for each experiment. Residual analysis showed that
this model can reasonably be applied to the data at
hand. Additionally, linear hypotheses tests were per-
formed in the above GLS model to test the effect of the
radiation dose in the presence of treatment (tested
hypotheses: brad+brad.EGF =0 ,brad+brad.AG = 0, etc).
Confidence intervals for the estimated coefficients were
calculated, and all hypotheses were tested based on the
Wald test. Separate analyses were conducted for the
three cell lines BHY, CAL-27 and HN for the time point
12 hours. The t-test was used to compare proliferation
in two conditions. Confidence intervals for the differ-
ence of means were calculated. All statistical analyses
were performed using the R statistical software http://
www.r-project.org, version 2.6.1.
Results
Blocking of EGFR decreased radiation induced migration
The cultured cell lines BHY, CAL-27 and HN were irra-
diated with 2, 5 and 8 Gy and monitored during 12
A B
Figure 2 A+B. Migrating cells of the wound healing assay. (A) Migrating cells of the wound healing assay -/+ irradiation were presented as
pictures (40 fold magnification, Axiovert 25, Carl Zeiss AG, Göttingen) 12 hours after irradiation. (B) The pictures were fused and the highlighted
cells were counted.
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time point and dose were calculated for each cell line.
Radiation induced a significant dose dependent migra-
tion of tumor cells after irradiation compared to the
control group (BHY: brad = 16, CI:[6;26], p = 0.003,
CAL-27: brad = 20, CI:[10;30], p < 0.001, HN: brad =3 7 ,
CI:[22;51], p < 0.001) (Figure 3).
T h ef i n d i n g so ft h ew o u n dh e a l i n ga s s a yw e r ec o n -
sistent with the results of the modified Boyden cham-
ber where a radiation induced migration was also
observed.
The stimulation of not irradiated (0 Gy) cells with EGF
lead to a significant increase of migration in all cell lines
(tested hypothesis bEGF =0 ,B H Y :bEGF = 137 CI:[66;209], p
<0 . 0 0 1 ,C A L - 2 7 :bEGF = 79, CI:[1;156], p = 0.048, HN: bEGF
= 211, CI:[113;308], p < 0.001). In contrast, the EGFR inhi-
bitor AG1478 significantly decreased migration (Figure 4).
The radiation-induced increase of migration was sig-
nificantly less pronounced after stimulation with EGF
(tested hypothesis brad.EGF =0 ,B H Y :brad.EGF = -26, CI:
[-41;-11], p < 0.001, CAL-27: brad.EGF = -26, CI:[-42,-10],
p = 0.002, HN: brad.EGF = -21, CI:[-41,-1;], p = 0.042) as
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Figure 3 Radiation induced migration. The number of migrating cells after irradiation with 0, 2, 5, and 8 Gy were determined by the wound
healing assay for the HNSCC cell lines BHY, CAL-27 and HN. Cells were grown to confluent monolayers, wounded by scratching the surface as
uniformly as possible with a pipette tip and afterwards irradiated. The number of migrated tumor cells in the wound was determined. The
means and standard errors of 9 tests per time point and dose were calculated after 12 hrs. An increased time dependent migration of tumor
cells after irradiation was observed after treatment compared to the control group of not irradiated cells (p < 0.009).
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Page 5 of 12well as after inhibition with AG1478 (tested hypothesis
brad.AG =0 ,B H Y :brad.AG = -17, CI:[-32;-2], p = 0.028,
CAL-27: brad.AG = -19, CI:[-35;-3], p = 0.021, HN: brad.
AG = -31, CI:[-52,-11], p = 0.003) than in control cells
(Figure 3). More precisely, migration did not increase
significantly with radiation dose in the cells stimulated
with EGF or inhibited with AG1478 (tested hypotheses:
brad+brad.EGF =0 ,brad+brad.AG = 0, p > 0.05), in contrast
to what happens in control cells.
Radiation-induced migration can be blocked by inhibition
of EGFR downstream pathways
Additionally to the above mentioned inhibition of the
EGF receptor, we blocked the downstream pathways of
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Figure 4 AG1478 inhibits radiation induced migration. Migration ability of the 3 different HNSCC cell lines after stimulation with EGF and
blocking of the EGFR with AG1478 was determined by the wound healing assay. The means of 9 tests per dosage were calculated after 12 hrs.
The increase of migration with increasing radiation dosis was significantly less pronounced after stimulation with EGF and after blocking of EGFR
with AG1478 than in control cells.
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Page 6 of 12EGFR: PI3K by LY294002 (30 minutes before radiation),
mTOR by rapamycin (1 hour before radiation) and
MEK1 by PD98059 (30 minutes before radiation). A sig-
nificant negative interaction between irradiation and the
inhibitors was seen in the HN cell line after 12 hours.
These findings indicate that the radiation-induced
migration of tumor cells was decreased significantly by
downstream inhibitors of the EGFR (Table 1). Migration
was most effectively decreased by blocking of PI3K
(LY294002) (Figure 5, Table 1).
After inhibition migration did not significantly
increase with radiation dose (tested hypotheses: brad
+brad.LY =0 ,brad+brad.Rapa =0 ,brad+brad.PD =0 ,p>
0.05) in all 3 cell lines, in contrast to what happens in
controls. Thus, inhibition seems to attenuate the influ-
ence of radiation on migration.
Proliferation subsided by inhibition of the PI3K/Akt
pathway
The strongest migration ability was observed at the dose
of 8 Gy. Therefore we focused on studying the effects
elicited at this radiation dose. We found a significant
decrease of proliferation after radiation with 8 Gy after
72 hours (BHY: CI:[-0.19,-0.12], p < 0.001; CAL-27: CI:
[-0.13,-0.05], p < 0.001; HN: CI:[-0.07,-0.01], p = 0.014).
Stimulation with EGF showed no significant effect on
proliferation (BHY: CI:[-0.11,0.06], p = 0.5; CAL-27: CI:
[-0.09,-0.01], p = 0.02; HN: CI:[0.02,0.09], p = 0.005)
without radiation, and no significant effect by simulta-
neously radiation with 8 Gy (BHY: CI:[-0.06,0.10], p =
0.57; CAL-27: CI:[-0.05,0.01], p = 0.19; HN: CI:
[-0.05,0.005], p = 0.10). After EGF receptor blockade
with AG1478 a significant decrease in proliferation was
observed, compared to the control group (BHY: CI:
[-0.27,-0.15],, CAL-27: CI:[-0.20,-0.14],, HN: CI:[-0.13,-
0.07], p < 0.001).
Inhibition of MEK1 with PD98059 or inhibition of
mTOR with rapamycin reduced significantly prolifera-
tion (BHY: CI:[-0.25,-0.12], CAL-27: CI:[-0.17,-0.10],
HN: CI:[-0.15,-0.07], p < 0.001). Blocking of PI3K with
LY294002 also reduced proliferation (BHY: CI:[-0.36,-
0.31], CAL-27: CI:[-0.26,-0.20], HN: CI:[-0.24,-0.18], p <
0.001) (Figure 6).
EGFR activation after irradiation was detected by Western
blot analysis
Protein was isolated at 0 hours and 24 hours after radia-
tion with 8 Gy. In all 3 cell lines we found a constitutive
activation of Akt and ERK. The stimulation with EGF
preceded an up-regulation of EGFR phosphorylation and
a phosphorylation of the downstream pathways. Block-
ade of the EGFR by AG1478 provoked a down regula-
tion of the receptor, the PI3K/Akt and the Raf/MEK/
ERK pathways. This effect continued during 24 hours.
After radiation an up regulation of the EGFR phosphor-
ylation was observed. The western blot results are pre-
sented in Figure 7.
Discussion
Survival rates of HNSCC patients have not improved
during the last decades [1]. HNSCC cells distinguish
through infiltrative growth in the surrounded area.
This is the reason for locally advanced disease in over
40% of patients [30]. Often tumor location does not
allow an in sano resection without severe impairment
in functions like swallowing, speech or respiration.
Therefore primary radiation therapy is an established
therapy of inoperable HNSCC, but the prognosis is
poor with five-year-cure rates rarely exceeding 50%
[4,31]. Additionally, radiation combined with che-
motherapy has been shown to be superior to radio-
therapy alone. There are benefits in terms of survival
and organ preservation [5]. Also new strategies like the
combined-treatment with cisplatin and hyperfractio-
nated radiation therapy maintained improved rates of
locoregional control, distant metastasis-free survival,
and cancer-specific survival [32]. But unfortunately, no
criteria for response to the radiation therapy have been
found.
In this study we could demonstrate for the first time a
radiation induced migration of HNSCC cells like it is
known for glioma cells [12,33]. Proliferating cells could
make a misleading result in the wound healing assay,
because they appear to imitate migration. However, this
effect is not caused by proliferating cells, because it was
shown in the MTT test that cell proliferation decreases,
when cells are irradiated.
Table 1 p-values
time [hrs] 12 24
treatment LY PD RA LY+ PD+ RA+ LY PD RA LY+ PD+ RA+
BHY < 0.001 0.781 0.050 0.089 0.023 0.021 < 0.001 0.007 0.011 0.131 0.125 0.005
CAL 0.001 < 0.001 0.003 0.027 0.107 0.088 < 0.001 < 0.001 < 0.001 0.154 0.301 0.024
HN < 0.001 < 0.001 < 0.001 0.002 0.041 0.014 < 0.001 < 0.001 < 0.001 0.001 0.003 < 0.001
The p-values are shown for the effect of blocking in controls (tested hypotheses: bLY =0 ,bPD =0 ,bRA = 0) and for the interaction (+) with radiation (tested
hypotheses: brad.LY =0 ,brad.PD =0 ,brad.RA = 0, etc). All interaction coefficients were negative, indicating that the effect of radiation on migration was weaker after
inhibition. (LY294002 (LY), PD98059 (PD), rapamycin (RA))
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mulation of the cells with EGF and by radiation treat-
ment. The mechanism might be a radiation induced an
autophosphorylation of the EGF receptor with an
activation of the downstream pathways, previously
observed [14,34]. Blockade of the EGFR by AG1478 that
leads to a significant inhibition of migration might sup-
port this observation.
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Figure 5 Migration ability of the HNSCC cell lines after blocking of the downstream pathways of the EGFR: PI3K by LY294002 (LY), mTOR
by rapamycin (RA) and MEK1 by PD98059 (PD) after irradiation with 0, 2, 5 and 8 Gy after 12 hours. Measurements were made in 9 experiments.
The effect of radiation on migration was significantly reduced by inhibitors of the downstream pathways of EGFR. (A cell line BHY, B cell line
CAL-27, C cell line HN)
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Page 8 of 12The EGFR plays an important role in tumor biology of
HNSCC. In a systematic review, the EGFR signaling is
associated with poor prognosis and response to therapy
in cervical cancer patients primarily treated with
chemoradiation [35]. Bonner et al. showed that the com-
bination of radiotherapy and cetuximab improved the
overall survival significantly [16]. Also Frampton found
in the setting of locally advanced, unresectable disease,
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Figure 6 A+B+C. Subsided proliferation after inhibition. Proliferation was assessed by the MTT test 12 hrs, 24 hrs and 72 hrs after irradiation
with 8 Gy or without irradiation (0 Gy). Proliferation subsided by radiation of the cell line CAL-27 and also by inhibition of the EGFR by AG1478
(AG) and after blocking of the downstream pathways of the EGFR: PI3K by LY294002 (LY), mTOR by rapamycin (Rapa) and MEK1 by PD98059
(PD), control.
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Page 9 of 12cetuximab plus radiation offers an alternative approach
to the current standard of care, namely platinum-based
chemotherapy plus radiotherapy and in recurrent and
metastatic HNSCC, cetuximab plus platinum-based che-
motherapy provides a first-line treatment of choice [36].
The reason for this might be a reduction in cell migra-
tion after blocking the EGFR in combination with radia-
tion, as we observed. Recent studies give an account of
Akt induced migration [37,38]. Therefore we focused on
the EGFR downstream pathways Raf/MEK/ERK and
PI3K/Akt and investigated whether a correlation with
the radiation-induced migration existed. A relation
between the PI3K/Akt signaling pathway and the migra-
tion was assumed, because inhibition of PI3K by
LY294002 and blockade of mTOR by rapamycin
involved a significant decrease of migrating cells. The
same effect was seen after inhibition of MEK1 by
PD98059. This was confirmed by our western blot
results: after radiation we observed an up-regulation of
phospho-EGFR, like described in a previous study [14].
The observed constitutive activation of Akt in our
HNSCC cell lines was recently confirmed by Bussink et
al. [39]. Additionally, clinical trials have shown a strong
and independent association between activated Akt
expression and treatment outcome [39]. Immediately
after inhibition of the PI3K, we saw a down regulation
of phospho-Akt, phospho-MEK and phospho-ERK on
protein level, whereas phospho-MEK1/2 and phospho-
ERK were up regulated through the lapse of the Akt
dependent phosphorylation of Raf1 on Ser259 after 24
hours as shown by Zimmermann et al. [40].
Actually, the therapy of patients with HNSCC in the
advanced stage III and IV implies primary radiotherapy
in combination with a chemotherapy [5] and altered frac-
tionation radiotherapy has a benefit for patient survival
[31]. Our data indicate that a change in the therapeutic
strategies of patients with HNSCC might be useful. Inhi-
bition of the EGFR and/or downstream pathways in com-
bination with the radiotherapy might be an option to the
conventional radiation and chemotherapy of patients
with HNSCC. In an animal model of nude mice it was
shown, that the inhibition of the PI3K by LY294002 in
combination with radiation induced a significantly better
outcome [41]. Also in human studies involving HNSCC
patients treated with a combination of radiation and
EGFR antagonization an overall survival benefit was
observed in 10%-15% of treated patients [42].
Conclusion
Our results demonstrate that the EGFR and the down-
stream signals like PI3K/Akt and Raf/MEK/ERK are
involved in radiation induced migration of HNSCC cells
and might be a future target for the therapy of HNSCC
in combination with radiotherapy.
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Figure 7 pEGFR activation by irradiation.T h eW e s t e r nb l o t
results were presented in figure form. Protein isolation was done 12
hrs after irradiation with 8 Gy. EGFR was stimulated by EGF and
inhibited by AG1478 (AG) and the downstream pathways of EGFR:
PI3K by LY294002 (LY), mTOR by rapamycin (Rapa) and MEK1 by
PD98059 (PD), control. We find an up-regulation of phospho-EGFR
after radiation.
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